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Abstract
Background: Prostate cancer cells in primary tumors have been typed CD10-/CD13-/CD24hi/
CD26+/CD38lo/CD44-/CD104-. This CD phenotype suggests a lineage relationship between cancer
cells and luminal cells. The Gleason grade of tumors is a descriptive of tumor glandular
differentiation. Higher Gleason scores are associated with treatment failure.
Methods: CD26+ cancer cells were isolated from Gleason 3+3 (G3) and Gleason 4+4 (G4) tumors
by cell sorting, and their gene expression or transcriptome was determined by Affymetrix DNA
array analysis. Dataset analysis was used to determine gene expression similarities and differences
between G3 and G4 as well as to prostate cancer cell lines and histologically normal prostate
luminal cells.
Results: The G3 and G4 transcriptomes were compared to those of prostatic cell types of non-
cancer, which included luminal, basal, stromal fibromuscular, and endothelial. A principal
components analysis of the various transcriptome datasets indicated a closer relationship between
luminal and G3 than luminal and G4. Dataset comparison also showed that the cancer
transcriptomes differed substantially from those of prostate cancer cell lines.
Conclusions:  Genes differentially expressed in cancer are potential biomarkers for cancer
detection, and those differentially expressed between G3 and G4 are potential biomarkers for
disease stratification given that G 4  c a n c e r  i s  a s s o c i a t e d  w i t h poor outcomes. Differentially
expressed genes likely contribute to the prostate cancer phenotype and constitute the signatures
of these particular cancer cell types.
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Background
The Gleason grade is a pathology characterization of pros-
tate tumors. Tumor glands can appear from well-differen-
tiated to poorly differentiated. The degree of
differentiation is scaled from 3 to 5 (grades 1 and 2 are no
longer in wide use), with 3 to indicate tumors with glan-
dular differentiation, 4 to indicate tumors with aglandular
differentiation, and 5 to indicate no differentiation with
cancer cells not organized into recognizable structures.
Each tumor is assigned a score of two Gleason grades.
Gleason 3+3 is associated with favorable outcomes and
patient survival while tumors containing 4 or 5 compo-
nents have a poorer prognosis. A molecular correlate of
the Gleason grade was reported where grade 3 could be
distinguished from grades 4 and 5 by gene expression,
whereas grades 4 and 5 were indistinguishable by gene
expression [1]. Another study, however, found a different
set of genes associated with degree of tumor differentia-
tion [2]. Reis et al. [3] found that a higher fraction (6.6%)
of intronic ncRNAs were significantly correlated to the
degree of prostate tumor differentiation (Gleason score)
when compared to unannotated genomic regions (1%) or
from exons of known genes (2%). The difference in gene
signatures reported by different laboratories has yet to be
explained, but is likely due to a combination of external
factors as well as actual biological difference. These stud-
ies have attempted to define a set of gene expression pro-
files as determined by microarray analysis that could
supplement the traditional diagnostics of pathology and
clinical parameters to predict disease course [4]. For exam-
ple, a 5-gene model was proposed that could segregate
recurrent from non-recurrent cancer [5]. Although gene
signatures have been shown to associate with Gleason
grade [6], none so far have been able to discriminate
locally invasive from non-invasive tumors.
We have previously shown that prostate tumors contained
multiple Gleason grades as well as multiple cancer cell
types distinguishable by their cluster designation (CD)
phenotypes [7,8]. CD antigens are cell surface molecules,
and each cell type has a unique complement of these mol-
ecules. This allowed us to isolate, for example, CD26+
luminal cells, CD104+ basal cells, CD49a+ stromal fibro-
muscular cells, and CD31+ endothelial cells from prostate
tissue samples by magnetic cell sorting (MACS) for micro-
array analysis using the Affymetrix GeneChip to deter-
mine cell type-specific gene expression or transcriptome
[9]. These cell type transcriptomes are a powerful tool to
discover lineage relationship between cell types. We
applied the same cell sorting methodology here to deter-
mine the transcriptome of CD26+ prostate cancer cells of
Gleason 3+3 and Gleason 4+4 tumor specimens. These
specimens, unlike those of 3+4 or 4+3, ensured that cells
representative of only grade 3 or 4 would be obtained. The
transcriptomes were then compared with each other to
identify differentially expressed genes, as well as with
those of the normal cell types. Furthermore, dataset com-
parisons between the transcriptomes of primary tumor
cells and prostate cancer cell lines, which were established
from metastatic lesions and showed unique CD expres-
sion [10,11], demonstrated that they were not representa-
tive of cells in primary tumors.
Methods
Prostate tumor tissue and cell sorting
Anonymized tissue samples were obtained at radical pros-
tatectomy under approval by the University of Washing-
ton Institutional Review Board. Pertinent pathology
information was requested from a research coordinator
who was authorized to access the patient database in the
Department of Urology. The resected glands were cut into
3-mm thick transverse blocks, and frozen sections from
representative right and left areas of the apex, middle and
base regions were stained to locate the tumor foci. With
the stained sections as guide, tumor tissue samples were
excised from the corresponding regions and placed in ster-
ile tubes. Processing of tissue pieces for cell sorting was as
described [9,12]. The collected samples were minced and
digested by collagenase type I (Invitrogen, Carlsbad, CA)
in serum-free RPMI1640 media supplemented with 10-8
M dihydrotestosterone on a magnetic stirrer at room tem-
perature overnight. The resultant cell suspension was fil-
tered with 70-μm Falcon cell strainer to remove debris,
diluted with equal volume of Hanks balanced salt solu-
tion (HBSS), and aspirated with 18-gauge needle. Cells
were pelleted by centrifugation and the digestion media
was analyzed by Western blotting for TIMP1 protein [13]
to gauge purity of the cancer specimens. The single cell
preparation was partitioned into stromal and epithelial
fractions on discontinuous Percoll density gradients
(Amersham Pharmacia, Piscataway, NJ). Cells banding at
the epithelial density were collected and used for sorting
with CD26 antibody. The tumor specimens of 05-179 and
08-032 weighed 0.6 g and 6 g respectively, and were above
the minimal weight requirement for cell sorting. The
pathology characteristics of tumors from which cancer
cells were obtained were as follows - 05-179: Gleason 3+3,
T2cN0Mx, 4.7 cc tumor volume; and, 08-032: Gleason
4+4, T3b, 27 cc tumor volume.
MACS cell isolation and FACS analysis of sorted cells
Gradient-purified epithelial cells were labeled with phy-
coerythrin (PE)-conjugated anti-CD26 (1:20; M-A261, BD
PharMingen, San Diego, CA) and sorted by MACS
(Miltenyi Biotec, Auburn, CA) as described previously for
the normal cell types [9]. Aliquots of positive and negative
cell fractions were analyzed by fluorescence activated cell
sorting (FACS, Becton Dickinson, Mountain View, CA) to
monitor sort efficiency as reported previously; only >85%
CD26+ fractions were used for microarray analysis [14].BMC Cancer 2009, 9:452 http://www.biomedcentral.com/1471-2407/9/452
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The sorted cancer cells were pelleted by centrifugation and
total RNA was extracted using RNaqueous (Ambion, Aus-
tin, TX).
Prostate cancer cell lines
Prostate cancer cell lines LNCaP, C4-2, CL1 (and its sub-
clones CL1.1 and CL1.31), DU145 and PC3 were cultured
and harvested for array analysis as described in our previ-
ous report on differential gene expression between LNCaP
and C4-2 [15].
Immunohistochemistry
Serial 5-μm sections were prepared from frozen blocks,
fixed in cold acetone, and processed for immunohisto-
chemistry using a three-step indirect avidin-biotin-perox-
idase procedure. The primary antibodies used were the
CD antibodies described in our previous reports [7,16].
Anti-Dlx1 (clone AB5724, Chemicon/Millipore, Billerica,
MA), was used at 1:500. Sections were counterstained
with hematoxylin. The immunostained sections were
imaged with Olympus BX41 microscope (Olympus,
Melville, NY) equipped with MircoFire digital camera
(Optronics, Goleta, CA). Images were processed with Pho-
toshop CS (Adobe Systems, San Jose, CA).
Western blot analysis
Cell-free tissue digestion media preparations (g tissue/ml
media) diluted in equal volume of HBSS were resolved by
gradient polyacrylamide gel electrophoresis and trans-
ferred to membrane filter for probing by AGR2 antibody
(1:500; 1C3, Abnova, Taipei, Taiwan). The 17-kDa AGR2
protein was visualized using ECL (GE Healthcare, Piscata-
way, NJ). Prostate specific antigen (PSA) antibody
(1:1,000; A67-B/E3, Santa Cruz Biotechnology, Santa
Cruz, CA) was used as sample loading control.
DNA array analysis
Quality and concentration of RNA were determined using
Agilent 2100 Bioanalyzer and RNA Nano or Pico Labchip
(Agilent Technologies, Santa Clara, CA) where appropri-
ate. Only RNA samples of sufficient concentration and
showed no degradation as evidenced by distinct 18S and
28S ribosomal bands were used for microarray experi-
ments. The Human Genome U133 Plus 2.0 GeneChips
(Affymetrix, Santa Clara, CA) were used for expression
profiling. The U133 array contains probesets representing
54,675 genes, splice variants, and ESTs. The GeneChips
were prepared, hybridized, and scanned according to the
protocols provided by Affymetrix (P/N 702232 Rev. 2)
[9,15]. In brief, 200 ng RNA was reverse transcribed with
poly (dT)/T7 promoter primer, and the cDNA was made
double-stranded.  In vitro transcription was performed
with biotinylated ribonucleotides, and the biotin-labeled
cRNA was hybridized to the GeneChips. The chips were
washed and stained with streptavidin-PE using FS-450 flu-
idics station (Affymetrix). Data was collected with Affyme-
trix GeneChip Scanner 3000. A total of three CD26+
prostate cancer array datasets were obtained from two
patients; with 05-179 analyzed twice and 08-032 analyzed
once. Two replicates were run for each prostate cancer cell
line: CL1, CL1.1, CL1.31, DU145 and PC3. Datasets pre-
viously obtained from five non-sorted whole-tissue tumor
specimens and their matched non-cancer specimens were
used for comparison [14]. All transcriptome datasets are
deposited in our public UESC database http://scgap.sys
temsbiology.net/, which makes them available for data
query [17].
Computational analysis of datasets
For differential gene expression, datasets were analyzed by
HTself, a self-self based statistical method for low replica-
tion microarrays [18] using a strategy very similar to that
described by Pascal et al. [14]. To apply this method, all
possible combination of pair-wise comparisons among
experiments were taken to create sets of ratios. Gene
expression level was defined as the normalized and sum-
marized intensities of each GeneChip probeset, and was
presented as its logarithmic value: X = log2(Normalized
intensity). This step was carried out using the standard
robust multi-array average (RMA) method [19], imple-
mented in the analysis pipeline SBEAMS [20]. The
strength of differential expression between any pair of
experiments was estimated by Mi = log2(ratio) = Xi-Xa,
where a represented one particular cell type and i repre-
sented each given cell type in the set: B (basal), L (lumi-
nal), S (stromal), E (endothelial), G3 (Gleason 3) or G4
(Gleason 4). To estimate reliability, the HTself method
used virtual self-self experiments (i.e., G3 cancer vs. G3
cancer) to derive intensity-dependent cutoffs. Accord-
ingly, a probeset was considered significantly differen-
tially expressed if at least 80% of its log-ratio
combinations were outside the 99.9% credibility inten-
sity-dependent cutoff. Moreover, an average greater than
8-fold difference in expression level was chosen. The com-
putational analysis results were verified by dataset query
of known differentially expressed genes. In principal com-
ponents analysis (PCA) of the various transcriptome data-
sets, a gene expression subspace was obtained that
brought out the principal sources of variability among
transcriptomes of the different prostate cell types. The
rotation matrix was obtained by using averages of XG3,
XG4, XL, XB, XS, and XE, and these were plotted as projec-
tions on the principal components space. The various
transcriptomes were then projected into this PCA-gener-
ated subspace, which could be rotated freely to visualize
the spatial separation of the individual nodes. Pathway
analysis of selected genes was done with KEGG [21].
Results
Gene expression of cancer cells of a Gleason 3+3 tumor
CD26+ prostate cancer cells were isolated from tumor
specimen 05-179, split into two aliquots, and each wasBMC Cancer 2009, 9:452 http://www.biomedcentral.com/1471-2407/9/452
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analyzed by DNA array. The 05-179 tumor was scored
Gleason 3+3 with negative margins (i.e., with no evidence
of extraprostatic spread). Cancer cells of the 05-179 tumor
glands were characterized as CD26+/CD13-/CD10- (Figure
1A), the predominant cancer cell type with a frequency of
~70% [7]. Absent expression of CD10 and CD13 distin-
guished these cancer cells from CD10+/CD13+ luminal
cells. Prostate basal cells were negative for CD10, CD13
and CD26, and basal cell CD markers were not detected in
the cancer by immunostaining (data not shown). Immu-
nostaining of all representative 05-179 tissue sections
containing cancer did not detect the CD10+ cancer cell
type, which has a frequency of ~30% [7].
For the single specimen of 05-179 cancer, statistical anal-
ysis of gene expression with traditional methods was not
applicable. Instead, HTself was used to analyze for differ-
ential gene expression between the CD26+ G3 cancer tran-
scriptome and the previously determined transcriptome
of the normal counterpart, CD26+ luminal [9]. Cluster
Prostate cancer cell gene expression Figure 1
Prostate cancer cell gene expression. A: Cancer CD phenotype. Serial sections of human prostate from specimen 05-179 
were stained for CD10, CD13, and CD26. Cancer glands in these serial sections are not stained for CD10 (top left) and CD13 
(top right), whereas a single benign gland (lower left in the photomicrographs) is; original magnification 200×. Cells in the can-
cer glands, like luminal cells of benign glands, are positive for CD26 (bottom left). In the higher magnification (400×, bottom 
right), the cancer cells show the characteristic prominent nucleoli. B: Dataset clustering. The relationship of the CD26+ cancer 
cell transcriptome to that of CD49a stromal, CD31 endothelial, CD26 luminal or CD104 basal is shown. Whole transcrip-
tomes were used to generate Euclidean distances. The self replicates of CD26+ cancer (blue) are in the middle. C: Gene 
expression in virtual Northern blot format. Affymetrix signal values are represented on a gray scale. The cell type-specific tran-
scriptomes are listed on the top with red arrowheads to identify CD26+ cancer and luminal. C4-2, CL1, CL1.1, CL1.31, 
DU145, LNCaP, PC3 are cancer cell lines.
CD13 CD10
CD26 CD26
AB
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analysis comparing the transcriptome datasets of CD26+
G3 cancer cells and the previously determined principal
cell types of the prostate [9] was summarized (Figure 1B).
The gene expression profile of CD26+ cancer was closer to
that of luminal than basal, in agreement with previous CD
phenotype analysis [7] and cell type-specific expression
data of cytokeratin subtypes [22].
The array data was reported as RMA-normalized Affyme-
trix signal intensities implemented in SBEAMS or as a
composite value Mi = log2(ratio) = Xi-Xa, where a repre-
sented cancer and i represented normal. For dataset query,
we enabled simple searches to display results in down-
loadable formats as previously described [17]. Query
results of signal intensity values were graphically shown
on a grayscale. Gene expression levels determined by
microarray for CD10/MME, CD13/ANPEP, CD24, CD26/
DPP4, and CD38 were concordant with immunohisto-
chemistry, i.e., CD26+/CD13-/CD10-; increased CD24
and decreased CD38 compared to luminal cells (Figure
1C). The CD26+ cancer cells also had elevated expression
of prostate cancer-associated genes AMACR (α-methyla-
cyl-CoA racemase), HPN (hepsin) and PCA3 (prostate
cancer antigen 3). These results indicated minimal con-
tamination of CD26+ luminal cells from non-cancer tissue
that might be present in the tumor specimen. In the same
display, the expression profiles of these CD in the various
prostate cancer cell lines were in agreement with their CD
expression previously determined by flow cytometry
[10,11]. For example, LNCaP and C4-2 are CD10+; C4-2
differs from LNCaP in being CD26+; PC3 is CD13+,
DU145 is CD24+. Overall, the gene expression and CD
phenotype of the CD26+ cancer cells differed substantially
from those of the cancer cell lines indicating that it is
unlikely that any of the cell lines, which were established
from metastatic lesions, could have derived from the
CD26+/CD10-/CD13- cancer cell type found in a majority
of tumors.
Differential gene expression between CD26+ G3 cancer
cells and CD26+ luminal cells analyzed by HTself identi-
fied 121 genes with increased cancer expression and 86
genes with decreased cancer expression by at least 8-fold
relative to luminal cells (see Additional File 1 for full list,
and Additional File 2 for self-self experiment and HTself
cutoff for differential expression). Although they were up-
regulated, AMACR and HPN were not among those with
the highest fold-increase in expression in this set. BRE,
which encodes a death receptor-associated anti-apoptotic
protein with an inhibitory function in the mitochondrial
pathway, was the most up-regulated, followed by
FLJ242562, R55784, MMP12, and KCNH8. IL24, which
was highly up-regulated in this dataset, was recently
found to be up-regulated in tumor-associated stromal
cells as well [14]. The many ESTs (highlighted in tan,
Additional File 1), e.g., KIAA0960, also contributed to the
signature of this prostate cancer cell type. Several Wnt
pathway genes (highlighted in yellow, Additional File 1)
were identified. Down-regulated genes by at least 8-fold
relative to luminal cells included peptidases [ENPEP
(glutamyl aminopeptidase), CPM (carboxypeptidase M),
in addition to ANPEP/CD13 and MME/CD10],
TNFRSF19 (involved in apoptosis), ADD3 (adducin,
important for cell-cell contact in epithelial tissues), GEDP
(the gene differentially expressed in the prostate), and
MSMB/PSP94. MSMB, KLK3/PSA and ACPP (prostatic acid
phosphatase) constitute the well-known three most abun-
dant prostatic secretory products. Unlike KLK3 and ACPP,
luminal expression of MSMB appears not to be regulated
by stromal influence [12], and is known to be down-regu-
lated in cancer cells [23].
Gene expression of cancer cells of a Gleason 4+4 tumor
The 08-032 tumor was scored Gleason 4+4, margin posi-
tive with seminal vesicle involvement. The Gleason scor-
ing of 08-032 indicated that virtually all the cancer cells
represented the Gleason grade 4 (G4) type while those of
05-179 the G3 type (no frozen tumor tissue block was
available for 08-032 for CD immunohistochemistry). Ver-
ification of the "purity" of this rather large (6 g) tumor
specimen, i.e., absence of non-cancer, was determined by
Western blot analysis of tissue collagenase digestion
media for TIMP1 protein (data published in ref. [14]).
TIMP1 protein is produced by luminal cells and not can-
cer cells [13]. Specimen 08-032 showed minimal reactiv-
ity for TIMP1, indicating a relatively pure sample with
little contamination by non-cancer. Differential gene
expression was analyzed between G3 and luminal cells,
and between G4 and G3 cells.
PCA (Figure 2) displayed the relatedness of the G3 and G4
transcriptomes to each other and to those of the other pre-
viously determined major cell types of the prostate: stro-
mal (S), luminal (L), basal (B), and endothelial (E). Their
particular placement suggested that, with respect to the
major differences in gene expression of cell types, G3 and
G4 were most similar to luminal (L) than any of the other
histologically normal prostate cell types. G4 was less sim-
ilar to luminal (L) than G3 as indicated by the longer sep-
aration between the respective data points. Neither the G3
nor the G4 transcriptome clustered near that of basal cells
(B) indicating that these CD26+ G3 and G4 cancer cells
were more characteristic of luminal cells than basal cells
in gene expression as well as CD phenotype.
Comparison of cancer cell and cancer tissue 
transcriptomes
The combined CD26+ cancer cell transcriptome datasets
were compared to those of five matched cancer (CP) and
non-cancer (NP) tissue specimens obtained also viaBMC Cancer 2009, 9:452 http://www.biomedcentral.com/1471-2407/9/452
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PCA projections of Gleason 3 and Gleason 4 cancer transcriptomes Figure 2
PCA projections of Gleason 3 and Gleason 4 cancer transcriptomes. A: Three-dimensional projection of G3 and G4 
transcriptomes with respect to those of prostate cell transcriptomes for stromal cells (S), luminal cells (L), endothelial cells (E), 
and basal cells (B) in a PCA-derived subspace. B: Two other orientations from a different point of perspective of the PCA 
space. The 3D coordinate system was obtained by performing the usual PCA, defining the rotation matrix related to the top 
three principal components and applying it to all datasets to create a subspace that highlights the expression particularities of 
each prostate cell type.
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Affymetrix GeneChips by us [14]. Pathology characteris-
tics of the CP tissue specimens are listed in Table 1. Cell
sorting was not possible for these CP samples because of
insufficient specimen quantity received (<0.5 g) for
MACS. Additionally, the presence of significant non-can-
cer in the samples (as indicated by TIMP1 Western) or that
of multiple CD cancer cell types (e.g., CD10+), especially
in the higher Gleason grades [7,8], was also problematic.
Some of the most differentially expressed genes identified
by HTself in cancer cells were compared to gene expres-
sion levels in whole tissue specimens (Figure 3). Data was
reported as a composite value of RMA-normalized
Affymetrix signal intensities: Mi = log2(ratio) = Xi-Xa. For
most, there was concordance between sorted cell and tis-
sue expression (e.g., down-regulation of ABP1 and up-reg-
ulation of BCMP11 in cancer). The main apparent
discordance was seen in genes analyzed as down-regu-
lated by cell datasets (AFF3, GDEP, RLN1) but not by tis-
sue datasets. This could be explained by the likelihood
that these genes were expressed by cell types other than
luminal or cancer epithelial in the tissue specimens.
Expression of stromal cell genes PENK [24] and THY1/
CD90 [14] was minimal indicating that CD26 sorting was
efficient enough to exclude CD90+ stromal cells [14], the
other major cell type of tumor tissue. These results also
indicated that processing for MACS did not significantly
affect gene expression.
Wnt signaling in prostate cancer
FZD8, WIF1 and SOX7 were identified by HTself as differ-
entially expressed between cancer and luminal cells, and
in whole tissue CP compared to NP (see Figure 3 and
Additional File 1). In the cancer cells as well as cancer cell
lines (data not shown), there was increased expression of
Wnt receptor FZD8; decreased expression of Wnt inhibi-
tor WIF1, which functions to sequester Wnt molecules
from receptor binding, and that of the transcription factor
SOX7. Stromal expression of WNT2 and SFRP4 suggests
Wnt signaling between stromal and epithelial cells in the
prostate. SFRP4 was also recently found to up-regulated in
tumor-associated stromal cells [14]. FZD8, WIF1, SOX7
identified in our analysis appeared to contribute to an ele-
vated expression of genes controlled by the Wnt molecule
(increase in receptors and decrease in inhibitors). Uncon-
Cancer cell vs. cancer tissue transcriptomes Figure 3
Cancer cell vs. cancer tissue transcriptomes. Profile of genes with ≥ 8-fold difference in expression in cancer compared 
to normal luminal cells as determined by analysis of sorted CD26+ (NP and CP) cells and whole tissue transcriptomes (NP and 
CP). Positive log2(Cancer/Normal) on the y-axis indicates increased cancer expression while negative log2 indicates decreased 
cancer expression.
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trolled Wnt signaling had been reported in many types of
cancer, including prostate [25]. Here, we identified three
key members of this signaling pathway that were abnor-
mally expressed in the CD26+ cancer cells.
Transcription factors with increased expression in cancer
The up-regulation and down-regulation of genes in the
cancer cells could also be attributed to the activation of
specific transcription factors such as ATF3, RUNX2, ERG,
DLX1 (and DLX2) identified in the cancer cell transcrip-
tomes. The fold increase in CD26+ cancer cells over lumi-
nal cells for ATF3 = 9, RUNX2 = 9, ERG = 21, DLX1 = 11
was similar to that for AMACR = 12 and HPN = 8. Prostate
cancer up-regulation has been previously documented for
ATF3 [26], RUNX2 [27] and ERG [28]. ATF3 is involved in
cell proliferation and survival, and is regulated by andro-
gen in prostate cancer cells. RUNX2 is overexpressed in
cancers that, like prostate cancer, metastasize to bone.
ERG is the fusion partner of TMPRSS2 in prostate cancer
[29]. DLX1 may be involved in epithelial-neuronal cell
conversion [30], as prostate cancer not infrequently dis-
plays neuroendocrine differentiation. Immunohisto-
chemistry verification of DLX1 gene expression levels with
anti-DLX1 showed protein expression was localized to the
cancer cell nuclei (Figure 4A).
Prostate cancer biomarkers
Genes encoding secreted or extracellular proteins with
increased expression in prostate cancer may serve as
potential biomarkers for diagnosis or prognosis. Several
genes that encode these proteins were upregulated in the
CD26+ cancer cells: AGR2, BCMP11, CEACAM5/CD66e,
CRISP3, KCNG3, KCNH8, LOX and NEO1 (Figure 4B).
These proteins could be measured in biospecimens by
using, for example, quantitative proteomics methods.
Except for AGR2 (anterior gradient 2, signal intensity at
4168 vs. 77 in luminal), their signal intensity indicated
that their abundance was in the moderate class (e.g., 268
for BCMP11; 217 for CRISP3). BCMP11 (breast cancer
membrane protein, also known as AGR3) was originally
discovered by proteomics in breast cancer cell lines T-47D
and MCF-7 [31]. BCMP11 was specific to cancer and not
found in normal ductal epithelial cells. The related AGR2
was previously shown to be androgen-inducible and over-
expressed in prostate cancer [32,33]. A ~19-kDa AGR2
protein was detected in cancer tissue preparation by mass
spectrometry of 2-D gel electrophoresis spot [34]. Western
blot analysis of CP vs. NP media confirmed overexpres-
sion of AGR2 protein in cancer (Figure 4C). Note that the
lower level of AGR2 protein in 08-032 CP was concordant
with decreased expression of AGR2 in this G4 cancer tran-
scriptome (see below). LOX and NEO1 also appeared to
be expressed by NP stromal cells, which would make
them less suitable as cancer biomarkers.
Genes potentially associated with node metastasis
The cancer cell transcriptomes were compared to the can-
cer cell lines for markers potentially associated with
advanced disease. These cells have been in culture for
many years and have undergone changes as a result; how-
ever, the expression of certain genes related to prostate
cancer metastasis could still be maintained. For example,
for lymph node metastasis, potentially important genes
could be identified through a comparison of the CD26+
cancer and LNCaP transcriptomes. Node metastases are
CD10+, whereas the CD26+ cancer cells are CD10-, so it is
possible that LNCaP is a representative of the CD10+ can-
cer cell type found in ~30% of prostate tumors and nearly
all positive nodes [8]. The two datasets were analyzed to
identify genes differentially expressed by ≥8-fold. All
genes known to be involved in CELL PROLIFERATION as
annotated in GeneOntology were filtered out. There are
other genes whose expression appeared to be linked to cell
culturing [35], but because they belong to different func-
tional categories they were not filtered out. Genes with
increased expression in LNCaP (and its lineage-related
C4-2, which has extensive shared gene expression [15])
were examined in CD26+ cancer. Figure 4D shows the
expression of cancer/testis melanoma antigens MAGE and
GAGE. Expression of GAGE-7 in LNCaP was reported in
the literature [36]. Kufer et al. [37] reported that MAGE
expression in circulating epithelial cells was detected sig-
nificantly more in patients carrying a higher risk of disease
recurrence than those with a lower risk. Patients with
metastasis had higher MAGE expression compared to
those with localized disease. There was also concordance
in expression between primary tumors and bone marrow.
In line with these genes, a gene called preferentially
expressed antigen in melanoma (PRAME) was also scored
in LNCaP and C4-2. Other candidates included DDC,
MANEA, ZWINT, while ERG and SERPINA3 were exam-
ples of genes scored with decreased expression in LNCaP
compared to CD26+ cancer. Genes with the least fold dif-
ference in expression, not unexpectedly, were those
encoding ribosomal proteins. For pathway visualization,
the LNCaP>CD26+ cancer analysis result was uploaded to
KEGG. Two notable networks for the data were ANDROGEN
AND ESTROGEN METABOLISM and FATTY ACID METABOLISM. It is
known that androgens and lipid metabolism are coupled
in LNCaP cells leading to accumulation of neutral lipids
[38].
Table 1: Prostate tumors used to generate CP tissue expression 
datasets.
case Gleason stage tumor volume (cc)
05-206 3+4 T3a 6
05-213 3+4 T2c 3.4
05-215 3+4 T2c 2.5
05-218 4+5 T3a 3
05-220 4+5 T3aN1 >5BMC Cancer 2009, 9:452 http://www.biomedcentral.com/1471-2407/9/452
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Prostate cancer genes Figure 4
Prostate cancer genes. A: Cancer expression of DLX1. Immunohistochemistry shows positive nuclei (three examples indi-
cated by red arrows, left panel) of cancer cells (case 04-030E) strongly stained. Cancer glands are negative for basal CD104 
(top right) and luminal CD10 (bottom right); original magnification 200×. B: Candidate prostate cancer biomarkers. Genes 
with increased expression (based on array signal values as used in Fig. 1C) in CD26+ cancer vs. luminal (arrowheads) that 
encode secreted - AGR2, CEACAM5, CRISP3, NEO1, membrane anchored - LOX, BCMP11 or transmembrane - KCNH8, 
KCNG3 proteins are shown. C: Western blot verification of AGR2 expression. In nearly all cases of CP except 08-032 (indi-
cated by arrow), AGR2 protein was detected at higher levels. AGR2 in any matched NP samples may be derived from diffusion 
from the cancer foci. D: Candidate biomarkers from LNCaP. Through dataset analysis, these genes were found differentially 
expressed between CD10-/CD26+ cancer and CD10+/CD26- LNCaP.
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Comparison between Gleason 3 and Gleason 4 cancer cells
HTself analysis of differentially expressed genes between
G3 and G4 identified 147 genes with increased expression
and 197 genes with decreased expression by at least 8-fold
in G3 relative to G4 cells (see Additional File 3 for full
list). In this set, the genes with the highest fold differential
expression included many of the secreted biomarker can-
didates (cf. Figure 4B). Their expression ratios in G3 vs. G4
cells were: AGR2 = 13.4, BCMP11 = 18.6, CEACAM5 =
8.6, CRISP3 = 0.1, KCNG3 = 0.5, KCNH8 = 2.0, LOX = 2.5,
NEO1 = 1.6 (Figure 5A). For most secreted biomarker can-
didates, expression was lower in G4 cells. The relative
expression of ANXA1 in the CD26+ cancer cells vs. luminal
cells was also decreased in G4 compared to G3, whereas
relative IL6 expression was increased. Decreased expres-
sion of ANXA1 has been associated with prostate cancer
and was postulated to enhance tumor aggressiveness via
the induction of IL-6 [39]. Loss of the androgen-regulated
tumor suppressor EAF2, which has been reported in high
grade tumors [40], was also evident in both G3 and G4
cells. Increased CRISP3 immunostaining in grade 4 (8.5-
fold) was reported by Bjartell et al. [41]. Note also the
decrease in BRE and the loss of CD38 expression, which
has as one of its functions to make a cell susceptible to
apoptotic signals. Differential CD38 staining has been
reported in prostate cancer by us [7]. Like CRISP3 and
KCNG3, AMACR, HOXC6, HPN, and PCA3 expression
was increased in G4 compared to G3. The G3/G4 ratios
were: AMACR = 0.7, HPN = 0.3, PCA3 = 0.6; plus DAD1 =
1.8, HSD17B4 = 3.1, MAOA = 0.7, three of the markers
reported to be up-regulated in grade 4 and 5 [1]. Of the 5-
gene signature presented by Singh et al. [6], only HOXC6
showed a 5-fold increase in our G4 dataset. Although the
whole tissue transcriptomes were derived from tumors of
Differential gene expression between Gleason 3 and Gleason 4 transcriptomes Figure 5
Differential gene expression between Gleason 3 and Gleason 4 transcriptomes. A: Expression levels of selected 
genes in G3 and G4 relative to luminal cells. B: Expression levels of these G3 and G4 genes in G3+4 vs. G4+5 tumors. C: Dif-
ferential expression of epithelial genes in G3 and G4 relative to luminal cells. D: Display for LNCaP genes in primary tumors. 
Positive log2(Cancer/Normal) on the y-axis indicates increased cancer expression and negative log2 indicates decreased cancer 
expression.
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mixed cancer cell types, they could be grouped into two
Gleason categories: three of Gleason 3+4, and two of
Gleason 4+5 tumors. Relative differential expression with
respect to higher Gleason score was verified for the down-
regulation of biomarker candidates AGR2, ANXA1,
BCMP11, BRE, CD24, FZD8, KCNH8, LOX and the up-
regulation of ANPEP, MME, HOX6C, and MAOA (Figure
5B).
The expression of epithelial genes such as ACPP, AZGP1
(zinc  α2-glycoprotein), KLK2/hK2, KLK3, and MSMB
showed a trend toward down-regulation relative to lumi-
nal cells (Figure 5C). With regard to the epithelial cytok-
eratins (KRT), relative expression levels of luminal cell
KRT8 and KRT18 were increased in G3 and G4, whereas
those of basal and intermediate cell KRT5, KRT14, KRT17
were significantly decreased. KRT19, which is expressed by
both basal and luminal epithelial cells and is thought to
be a marker of the transit-amplifying population [42], was
slightly increased in G3, but decreased in G4 with respect
to luminal cells.
The LNCaP genes as potential markers of metastatic
potential were also queried between G3 and G4 (Figure
5D). Note the decrease in ERG (2.3-fold) and SERPINA3
(53.5-fold) in G4 cells as that found in the G3/LNCaP
comparison. Of the others, PRAME showed a 13.6-fold
increase in G4. No expression of MAGE or GAGE was
seen.
For pathway visualization, the G3 vs. G4 cancer analysis
result was uploaded to KEGG. Notable networks for the
data included EXTRACELLULAR MATRIX-RECEPTOR INTERAC-
TION and CYTOKINE-CYTOKINE RECEPTOR INTERACTION. One
of the most differentially up-regulated genes in G4 cells
was CCL3 (chemokine C-C motif ligand, Additional File
3). CCL3 encodes the α subunit of MIP1 (macrophage
inflammatory protein-1), which is active in recruitment
and activation of polymorphonuclear leukocytes in acute
inflammation. The β subunit gene, CCL4, was also differ-
entially expressed in G4. CCL4 was recently reported to be
associated with prostate cancer recurrence by Blum et al.
[43].
Comparison with other cancer datasets
Two publicly available high throughput gene expression
datasets available for comparison with our data were
GSE6099 [44] and GSE5132 [1]. The GSE6099 dataset is
comprised of n = 104 laser-capture microdissected (LCM)
cells for non-cancer, premalignant prostatic intraepithe-
lial neoplasia (PIN), primary tumor, and metastasis ana-
lyzed against non-cancer prostate RNA obtained from a
commercial source in two-color cDNA arrays. The arrays
contained 20,000 probes mapped to 9,704 known genes,
from which the overlap with the HU133 array was 7,698
genes. The GSE5132 dataset is comprised of n = 30 LCM
cells for non-cancer, Gleason grades 3, 4 or 5 cancer ana-
lyzed against normal adjacent glands in two-color cDNA
arrays. The arrays contained 15,488 probes mapped to
3,615 known genes, from which the overlap with HU133
was 3,135 genes. The overall correlation (~0.2) between
the CD26+ G3 cancer dataset and these, which included
Gleason 3 cancer, was rather poor (Figure 6A). It is impor-
tant to bear in mind that the comparison involved differ-
ent array platforms (Affymetrix DNA vs. cDNA arrays), cell
isolation methods (MACS vs. LCM), cancer/normal com-
parison (sorted normal cells vs. commercial RNA of nor-
mal  vs. adjacent normal glands). When GSE6099 and
GSE5132 were compared for the best correlation possible,
the result was also poor with a mean of 0.25 (range: 0.16-
0.36 for all possible permutations). We created an Excel-
based query tool to display the expression pattern of a par-
ticular gene across all these datasets (Figure 6B). For exam-
ple, MME/CD10 was down-regulated in the CD26+ G3
cancer cells, and both GSE datasets showed agreement
(some expression was detected in the stromal cells of
GSE6099). The fold decrease was largest between CD26+
G3 cancer cells and luminal cells, as possible from a cell-
to-cell comparison. FZD8 was shown up-regulated in
CD26+ G3 cancer cells, and the GSE6099 dataset also
showed agreement; GSE5132 contained no information
regarding FZD8. For the candidate secreted biomarkers,
there was no information for CRISP3, KCNG3 or KCNH8
in GSE6099; for BCMP11, CEACAM5, CRISP3, KCNG3 or
LOX in GSE5132. AGR2 in the GSE6099 dataset is shown,
and increased expression was detected in PIN. Immuno-
histochemistry had previously shown AGR2 expression in
high-grade PIN [32].
Discussion
Transcriptome analysis of CD26+ prostate cancer cells
demonstrated that it was possible to isolate and character-
ize gene expression in cancer cells from solid tumors
weighing 0.5 g or more utilizing our cell sorting method-
ology. The extensive tissue processing also did not appear
to alter substantially the gene expression profiles of the
cancer cells or the tumor-associated stromal cells reported
previously [14]. Because each tumor could be unique in
certain aspects we chose to determine differentially
expressed genes by HTself data analysis rather than treat-
ing them as biological replicates of each other. The CD26+
cancer datasets obtained were representative of Gleason
grades 3 and 4. Grade 3 tumors show a glandular mor-
phology whereas grade 4 tumors are typically less glandu-
lar. Sorting for grade 5 is problematic as Gleason 5+5
tumors are rarely seen. According to many pathologists,
cells of Gleason grade 3 are those that are first recogniza-
ble as cancerous. Compared to the normal counterpart
luminal cells, the expression of a variety of genes was
found to be different. This could be due to the alteredBMC Cancer 2009, 9:452 http://www.biomedcentral.com/1471-2407/9/452
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Dataset comparison to 05-179 Gleason 3 transcriptome Figure 6
Dataset comparison to 05-179 Gleason 3 transcriptome. A: Dataset correlation. Each node represents a single dataset 
with the first data point being the 05-179 CD26+ cancer transcriptome (in red). In the GSE6099 display, the flanking lowest 
correlates are those of non-cancer and stromal cells (see B). B: Single-gene query displays. Shown are those for MME/CD10 in 
both GSE6099 (top), where the laser-captured Gleason grade 3's are indicted by black dots, and GSE 5132 (bottom); FZD8 
and AGR2 in GSE6099. Positive log2(Cancer/Normal) on the y-axis indicates increased cancer expression and negative log2 
indicates decreased cancer expression.
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expression of several transcription factors. Some of the
genes identified are involved in cell division and response
to apoptotic signaling. Genes of the Wnt pathway, which
is important in epithelial-stromal cell interaction,
appeared to be dysregulated to produce increased Wnt sig-
naling in the cancer cells. Targeting this particular path-
way may prove effective in prostate cancer.
The cancer cell types profiled in this study were the CD10-
luminal-like types, although one populated a Gleason
3+3 tumor and the other a Gleason 4+4 tumor. Their
respective transcriptomes represent the signatures of two
distinct prostate cancer cell types. As greater numbers of
cancer cell types from different cases are analyzed, it will
be interesting to determine if dissimilarities in gene
expression increase with higher Gleason grades. This
could be visualized using PCA. The number of possible
prostate cancer cell types is currently unknown, and
tumor behavior could be dependent on its composition of
various cancer cell types. For example, the CD10+ type is
associated with lymph node metastasis and poor out-
comes [8,45]. Isolation of this cell type is hampered by the
fact that luminal cells are also CD10+ and CD10 staining
of biopsy is currently not a standard practice. Other cell
types like CD44+ [46] are even more rarely encountered.
The identification of candidate biomarkers for cancer
detection and disease stratification in this study is of prac-
tical utility. Their identity would provide for a targeted
approach to analyze for their presence in body fluids such
as urine and blood. Genes that encode secreted proteins
are particularly useful as most, if not all, clinical tests are
based on immunodetection of these types of molecules.
Since cancer cells are non-functional, it was not expected
that many such proteins would be found. As can be
inferred from the array signal intensity levels, expression
of the major functional prostatic secretory proteins ACPP,
AZGP1, KLK2, KLK3, and MSMB was down-regulated in
the cancer cells compared to the luminal cells. Of the can-
didates, AGR2 appeared most promising. AGR2 is a rela-
tively small protein and is produced apparently at a high
level based on the array signals (>4000). AGR2 was also
readily detectable in the tissue digestion media of cancer
specimens by Western blot analysis. AGR2 expression
may be decreased in higher Gleason tumors. Thus, AGR2
could potentially serve as a target biomarker for early dis-
ease detection. In contrast, the secreted CCL3/CCL4 could
serve as a biomarker of tumors containing a G4 cancer cell
type. Care must be taken to ensure that these potential
biomarker proteins are not produced significantly by
other cell types. Expression of these candidates will be
examined in greater detail by tissue microarray analysis. A
multimarker panel could conceivably be generated to
incorporate all informative genes to diagnose prostate
cancer.
Conclusions
In summary, we have determined the transcriptomes of
CD26+  primary prostate cancer cells isolated from
Gleason grade 3 and grade 4. Grade 4 is usually associated
with poor clinical outcomes. Therefore, genes differen-
tially expressed between these two grades have prognostic
potential. The method we have described to isolate pri-
mary prostate cancer cells for transcriptome analysis
should be applicable to other solid tumors.
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